Northeastern U.S. Children Show Signs of Worse Asthma in Wildfire Smoke
December 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Anoro Ellipta
Synonyms :
umeclidinium bromide/vilanterol inhaled
Class :
Anticholinergics, Respiratory, Beta2 Agonists, Inhalant Combos
Brand Name :
Anoro Ellipta
Synonyms :
umeclidinium bromide/vilanterol inhaled
Class :
Anticholinergics, Respiratory, Beta2 Agonists, Inhalant Combos
Dosage Forms & Strengths
Inhalation powder
(62.5mcg/25mcg)/actuation
Chronic Obstructive Pulmonary Disease (COPD)
Indicated for long-term maintenance of COPD that includes emphysema and chronic bronchitis
62.5 mcg/25mcg as one actuation inhaled orally each day
Do not exceed more than one inhalation each day
Safety & efficacy are not seen in pediatrics
Refer to the adult dosing
Actions and Spectrum:
Actions:
umeclidinium bromide selectively antagonizes the muscarinic M3 receptors in the airway smooth muscles, preventing the binding of acetylcholine and inhibiting the bronchoconstriction caused by acetylcholine.
umeclidinium bromide produces bronchodilation by relaxing the smooth muscles in the airways, improving airflow, and reducing airway resistance. It also helps to reduce mucus production.
vilanterol is a long-acting beta2-adrenergic agonist (LABA). It selectively stimulates the beta2-adrenergic receptors in the bronchial smooth muscles, activating adenylate cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) levels.
Spectrum:
The combination of umeclidinium bromide and vilanterol provides a dual broncho dilatory effect due to their distinct mechanisms of action. This combination medication offers a broader spectrum of bronchodilation compared to using either component alone. By targeting different receptors and signaling pathways, umeclidinium bromide/vilanterol can synergistically relax the smooth airway muscles, reduce airway resistance, and improve lung function in patients with COPD.
Frequency defined
1-10%
Pharyngitis (2%)
Diarrhea (2%)
Neck pain (1%)
Chest pain (1%)
Pain in extremities (2%)
Muscle spasms (1%)
Sinusitis (1%)
Constipation (1%)
Lower respiratory tract infection (1%)
<1%
Productive cough
Dry mouth
GERD
Vomiting
Dyspepsia
Abdominal pain
Musculoskeletal chest pain
Chest discomfort
Ventricular extrasystoles
Supraventricular extrasystoles
Asthenia
Atrial fibrillation
Myocardial infarction
Rash
Conjunctivitis
Pruritus
Contraindication/Caution:
Contraindications
Cautions
Caution should be maintained in the people with
Pregnancy consideration:
No data is available regarding the well-controlled studies on pregnant women.
Breastfeeding warnings:
No data is available regarding the excretion of drugs in breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology
umeclidinium bromide selectively antagonizes the muscarinic M3 receptors in the smooth muscles of the airways. By blocking the binding of acetylcholine to these receptors, it inhibits the bronchoconstrictive effects of acetylcholine, leading to bronchodilation. umeclidinium bromide primarily acts locally in the lungs.
vilanterol selectively stimulates the beta2-adrenergic receptors in the smooth muscles of the airways. This stimulation activates adenylate cyclase, increasing cyclic adenosine monophosphate (cAMP) levels within the cells. Elevated cAMP levels cause relaxation of the bronchial smooth muscle, leading to bronchodilation and improved airflow. vilanterol primarily acts locally in the lungs.
Pharmacodynamics
The combination of umeclidinium bromide and vilanterol provides a dual bronchodilatory effect. By targeting different receptors and signaling pathways, the combination produces a synergistic effect, resulting in enhanced bronchodilation and improved lung function compared to using either component alone.
The pharmacodynamics of umeclidinium bromide/vilanterol help alleviate symptoms associated with COPD. Promoting bronchodilation and improving airflow helps patients with COPD breathe more easily.
Pharmacokinetics
umeclidinium bromide:
Absorption
After inhalation, umeclidinium bromide is absorbed into the systemic circulation. The absolute bioavailability of umeclidinium bromide following inhalation is low, as most of the inhaled dose remains in the lungs.
Distribution
umeclidinium bromide has a large volume of distribution, indicating extensive distribution into the tissues.
Metabolism
umeclidinium bromide undergoes minimal metabolism in the liver.
Elimination and Excretion
umeclidinium bromide is eliminated mainly through fecal biliary excretion, with minimal renal excretion.
vilanterol:
Absorption
Following inhalation, vilanterol is absorbed into the systemic circulation. The absolute bioavailability of vilanterol following inhalation is low, as most of the inhaled dose remains in the lungs.
Distribution
vilanterol has a large volume of distribution, indicating extensive distribution into the tissues.
Metabolism
Hepatic enzymes primarily metabolize vilanterol, including cytochrome P450 3A4 (CYP3A4). The main metabolic pathway involves O-dealkylation to form the inactive metabolite GW642444.
Elimination and Excretion
The metabolites of vilanterol are eliminated primarily through fecal excretion, with a smaller portion excreted in the urine.
Combination Pharmacokinetics:
When used as a fixed-dose combination, the pharmacokinetics of umeclidinium bromide and vilanterol can be influenced by each other. However, due to their low systemic bioavailability, most of the administered dose of both components remains in the lungs, where their local pharmacological effects occur.
Administration:
Open the inhaler device according to the manufacturer’s instructions. Some inhalers require priming before the first use. Follow the priming instructions if necessary. Exhale away from the inhaler to empty your lungs as much as possible before using the inhaler.
Hold on the inhaler erect with the mouthpiece pointing towards you. Ensure that the mouthpiece is clean and free from obstructions. Fix the inhaler in the lips as a seal.
Slowly breathe deeply through your mouth, and at the same time, press down the dose-release button on the inhaler to release the medication. After inhaling the medication, remove the inhaler from your mouth. Hold your breath for some time, and then exhale slowly and gently.
Patient information leaflet
Generic Name: umeclidinium/vilanterol
Pronounced: ue-ME-kli-DIN-ee-um/vye-LAN-ter-ol
Why do we use umeclidinium and vilanterol?
umeclidinium/vilanterol are combined as fixed-dose medications for treating chronic obstructive pulmonary disease (COPD).
The fixed-dose combination of umeclidinium/vilanterol simplifies the treatment regimen for patients by combining two different bronchodilators into a single inhaler.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
